Recce Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Recce Pharmaceuticals has a total shareholder equity of A$534.2K and total debt of A$2.2M, which brings its debt-to-equity ratio to 418.1%. Its total assets and total liabilities are A$5.5M and A$4.9M respectively.
Key information
418.1%
Debt to equity ratio
AU$2.23m
Debt
Interest coverage ratio | n/a |
Cash | AU$4.01m |
Equity | AU$534.18k |
Total liabilities | AU$4.94m |
Total assets | AU$5.47m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RECE.F's short term assets (A$4.8M) exceed its short term liabilities (A$4.6M).
Long Term Liabilities: RECE.F's short term assets (A$4.8M) exceed its long term liabilities (A$291.0K).
Debt to Equity History and Analysis
Debt Level: RECE.F has more cash than its total debt.
Reducing Debt: RECE.F had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RECE.F has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: RECE.F is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.